Human Genome Sciences Shareholder Alert: The Briscoe Law Firm & Powers Taylor, LLP Investigate Sale of Human Genome Sciences ...
17 Juillet 2012 - 4:53PM
Business Wire
Former United States Securities and Exchange Commission attorney
Willie Briscoe and the securities litigation firm of Powers Taylor,
LLP are investigating the sale of Human Genome Sciences (“HGSI”)
(NASDAQ: HGSI) to GlaxoSmithKline plc for shareholders. Under the
proposed transaction, HGSI shareholders will only receive $14.25 in
cash for each share of HGSI stock owned, well below the 52 week
high of $23.84.
If you are an affected investor, and you want to learn more
about the lawsuit or join the action, contact Patrick Powers at
Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at
patrick@powerstaylor.com, or Willie Briscoe at The Briscoe Law
Firm, PLLC, (214) 706-9314, or via email at
WBriscoe@TheBriscoeLawFirm.com. There is no cost or fee to you.
The transaction is valued at approximately $3 billion.
The investigation centers on whether HGSI shareholders are
receiving adequate compensation for their shares in the buyout,
whether the transaction undervalues HGSI stock, and whether HGSI’s
board attempted to obtain the highest share price for all
shareholders prior to agreeing to the deal. According to at least
one analyst with Yahoo! Finance, the true inherent value of HGSI
may be as high as $23.00, well above the proposed transaction
price. “Due to the lack of a significant premium to the
shareholders and other factors, we believe that the transaction may
undervalue HGSI stock. Our lawsuit will seek to obtain the highest
share price for all shareholders,” said shareholder rights attorney
Willie Briscoe.
The Briscoe Law Firm, PLLC is a full service business litigation
and shareholder rights advocacy firm with more than 20 years of
experience in complex litigation and transactional matters.
Powers Taylor, LLP is a boutique litigation law firm that
handles a variety of complex business litigation matters, including
claims of investor and stockholder fraud, shareholder oppression,
shareholder derivative suits, and security class actions.
Human Genome Sciences (NASDAQ:HGSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Human Genome Sciences (NASDAQ:HGSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Human Genome Sciences, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Powers Taylor, LLP